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TGFbeta 2Mandibuloacral dysplasia type A (MADA) is a rare disease caused by mutations in the LMNA gene encoding A
type lamins. Patients affected by mandibuloacral dysplasia type A suffer from partial lipodystrophy, skin
abnormalities and accelerated aging. Typical of mandibuloacral dysplasia type A is also bone resorption at
deﬁned districts including terminal phalanges, mandible and clavicles. Little is known about the biological
mechanism underlying osteolysis in mandibuloacral dysplasia type A. In the reported study, we analyzed an
osteoblast primary culture derived from the cervical vertebrae of a mandibuloacral dysplasia type A patient
bearing the homozygous R527H LMNAmutation. Mandibuloacral dysplasia type A osteoblasts showed nuclear
abnormalities typical of laminopathic cells, but they proliferated in culture and underwent differentiation
upon stimulation with dexamethasone and beta-glycerophosphate. Differentiated osteoblasts showed proper
production of bone mineral matrix until passage 8 in culture, suggesting a good differentiation activity. In
order to evaluate whether mandibuloacral dysplasia type A osteoblast-derived factors affected osteoclast
differentiation or activity, we used a conditioned medium from mandibuloacral dysplasia type A or control
cultures to treat normal human peripheral blood monocytes and investigated whether they were induced to
differentiate into osteoclasts. A higher osteoclast differentiation and matrix digestion rate was obtained in the
presence of mandibuloacral dysplasia type A osteoblast medium with respect to normal osteoblast medium.
Further, TGFbeta 2 and osteoprotegerin expression were enhanced in mandibuloacral dysplasia type A
osteoblasts while the RANKL/osteoprotegerin ratio was diminished. Importantly, inhibition of TGFbeta 2 by a
neutralizing antibody abolished the effect of mandibuloacral dysplasia type A conditioned medium on
osteoclast differentiation. These data argue in favor of an altered bone turnover in mandibuloacral dysplasia
type A, caused by upregulation of bone-derived stimulatory cytokines, which activate non-canonical
differentiation stimuli. In this context, TGFbeta 2 appears as a major player in the osteolytic process that
affects mandibuloacral dysplasia type A patients.c/o IOR, Via di Barbiano 1/10, I-
051583593.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The osteoblast, a bone-speciﬁc mesenchymal cell type, is respon-
sible for the synthesis and secretion of most proteins of the organic
bone extracellular matrix and also expresses genes that are necessary
and sufﬁcient to induce bone mineralization [1]. Osteoblasts have athird function: they are required for osteoclast differentiation, and
thereby for bone resorption. Two main genes required for osteoclast
differentiation are expressed in osteoblasts, M-CSF and RANKL, which
act as positive regulators of osteoclast differentiation. Moreover,
osteoblasts express osteoprotegerin, a soluble TNFα receptor that acts
as a decoy receptor for RANKL and negatively regulates osteoclast
differentiation [2]. Thus, soluble factors produced by osteoblasts may
be used to obtain differentiation of blood precursors into active
osteoclasts [3].
Lamin A/C is a nuclear lamina constituent implicated in a number
of inherited disorders affecting muscle, adipose tissue, and nerves or
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Among syndromic laminopathies, MADA shows a clinical phenotype
characterized by partial lipodystrophy, slightly accelerated aging and
osteolysis [7]. The biological mechanism implicated in the osteolytic
process is not well understood. However, four recent papers shed light
on that aspect of MADA. The paper by Rauner et al. [8], performed in
human precursors where lamin A/C expression was knocked-down,
showed that lamin A/C is required for proper osteoblast differentia-
tion while absence of the nuclear lamina constituent activates RANKL-
dependent osteoclastogenesis. The paper by Akter et al. [9], performed
in human bone marrow precursors subjected to lamin A/C siRNA-
mediated inhibition, presented evidence of increased differentiation
of bone progenitor cells towards the adipogenic lineage. The latter
result was also obtained in bone marrow progenitors from Zmpste24
null mice, an animal model showing accumulation of prelamin A due
to knockout of its speciﬁc endoprotease [10]. A paper published by our
groups [11] showed that accumulation of prelamin A favors osteoclast
differentiation from human peripheral blood monocytes. All these
data argue in favor of an altered bone turnover associated with
absence of mature lamin A and/or accumulation of the unprocessed
lamin A precursor. The studywe report in the present paper is the ﬁrst
one performed in human osteoblasts from a laminopathic patient
affected by osteolysis. We show proper differentiation, but increased
expression of TGFbeta and osteoprotegerin in MADA osteoblasts. We
further show that MADA osteoblast conditioned medium is able to
activate osteoclast precursors at higher rate relative to medium
derived from control osteoblast cultures. How osteoprotegerin and
TGFbeta could mediate the increased stimulation of osteoclast
progenitors is discussed in the paper. The reported data suggest a
key role for TGFbeta in triggering the osteoclastogenic activity of
MADA osteoblasts.Table 1
List of primers used in this study.
OPG (NM_002546.2) Sense GAAGGGCGCTACCTTGAGAT
Antisense GCAAACTGTATTTCGCTCTGG
RANKL (NM_003701.2,
NM_033012.2)
Sense TGATTCATGTAGGAGAATTAAACAGG
Antisense GATGTGCTGTGATCCAACGA
TGFβ2 (NM_003238.2) Sense CCAAAGGGTACAATGCCAAC
Antisense CAGATGCTTCTGGATTTATGGTATT
GAPDH (NM_002046.3) Sense AGCCACATCGCTCAGACAC
Antisense GCCCAATACGACCAAATCC
COL1A1 (NM_000088.3) Sense CCCCTGGAAAGAATGGAGAT
Antisense AATCCTCGAGCACCCTGA
BGLAP (NM_199173.2) Sense GGCGCTACCTGTATCAATGG
Antisense TCAGCCAACTCGTCACAGTC
SPARC (NM_003118.2) Sense ACCCGCTTTTTCGAGACC
Antisense CAAGATCCTTGTCGATATCCTTCT2. Materials and methods
2.1. Cell cultures and differentiation
Primary cultures of human osteoblasts (CTRL HOB) were obtained
from normal bone removed during orthopedic surgery of three
different patients, as previously described [12], and obtained accord-
ing to all the local ethical committee issues. Informed consent had
been obtained from patients. Isolated cells were maintained, in
Dulbecco's Modiﬁed Eagle Medium supplemented with 10% FBS,
100 μmol/L ascorbic acid-2 phosphate and 10−8 M dexamethasone.
[13].
Osteoclasts were obtained from peripheral blood mononuclear
cells (PBMC) as described previously [11]. Fresh buffy coats (AVIS,
Bologna, Italy) were diluted with PBS, layered over Hystopaque
(Sigma, St. Louis, MO), and centrifuged at 900g for 30 min. The
mononuclear cells were extracted from the interphase of the PBS and
Hystopaque and centrifuged at 400g for 5 min. Cells were rinsed in PBS
and seeded on tissue-culture glass or plastic ware in D-MEM
supplemented with 10% FCS and incubated at 37 °C in a humidiﬁed
5% CO2 atmosphere. Cells were seeded at the density of 3,000,000/cm2.
After 1 h, medium was discarded and replaced with conditioned
medium from conﬂuent cultures of CTRL HOB or MADA osteoblasts
(MADA HOB) (25% conditioned medium and 75% normal medium).
Conditioned medium was replaced every 4 days for 14 days. In order
to verify the differentiation of mononuclear cells to osteoclasts, after
8 days of culture, cells were analyzed for tartrate resistant acid
phosphatase (TRACP) activity by cytochemistry (Acid Phosphatase
Leukocyte assay, Sigma), and stainedwithHoechst 33258 (1.25 g/mL).
TRACP-positive cells containing 3 or more nuclei were considered to
be differentiated osteoclasts. If not differently speciﬁed, the average
value for controls is the average of results of three different CTRL HOB
cultures.2.2. Gene expression analysis
RNA isolation and reverse transcription were performed as
previously described [11]. Total RNA was isolated using Rneasy Mini
Kit (Qiagen GmbH, Hilden, Germany) from semi-conﬂuent osteoblast
cultures following manufacturer's instructions. RNA was reverse
transcribed into cDNA using the Advantage RT for PCR Kit (Clontech
Laboratories, Palo Alto, CA). OPG, RANKL or TGFbeta expression was
evaluated by real time PCR, performed using a Light Cycler
instrumentation (Roche Diagnostics), by amplifying 1 μg of cDNA
and the Universal Probe Library system (Roche Applied Science).
Probes and primers were selected using a web-based assay design
software (ProbeFinder https://www.roche-applied-science.com).
Forward and reverse primers are listed in Table 1. The ampliﬁcation
protocol was: 95 °C for 10 min, 95 °C for 10 s, 60 °C for 30 s, and 72 °C
for 1 s for 45 cycles, 40 °C for 30 s. The results are expressed as ratio
between gene of interest and GAPDH reference gene. The experiments
were performed in duplicate.
2.3. Resorption assay
To evaluate the resorption activity in osteoclast cultures we used the
Osteolyse assay (Cambrex Bio Science Walkersville, Inc., Charles City,
IA). Cells were cultured in conditioned medium from MADA osteoblast
cultures or controls for 10 days. Supernatants were collected and the
fraction of collagen Type I released in the medium as a consequence of
the osteoclast-mediated resorption activity was quantiﬁed as follows.
The Osteolyse assay provides a quantitative assessment of in vitro
osteoclast-mediated degradation of human bone Type I collagen by
directly measuring the release of Europium-labeled collagen fragments
via time resolved ﬂuorescence. At the end of incubation time (10 days),
the collected cell culture supernatants were centrifuged, and 10 of the
200 μL of the supernatantwere added to200 μL of FluorophoreReleasing
Reagent. Theﬂuorescenceof eachwell of theassayplatewasdetermined
in a time-resolvedﬂuorescence ﬂuorimeter (Wallac Victor, exc. 340 nm,
ems. 615 nm). For the evaluation of the effect of the treatment with an
anti-TGF-beta-2 antibody, cells were incubated for ten days with the
supernatants obtained from the CTRL HOB and MADA HOB cultures, as
described above, added or not addedwith 0.03 μg/ml of a polyclonal IgG
anti-TGF-b2 antibody (Abcam), or with 0.03 μg/ml of an IgG control
antibody (polyclonal anti-emerin antibody, Santa Cruz Biotechnology).
2.4. ELISA
Amultiple sandwich enzyme immunoassay was performed for the
quantitative determination of OPG and sRANKL released from CTRL
HOB or MADA osteoblasts, as previously described [14]. For OPG
detection, the following antibodies were used: mouse anti-human
OPG (2 mg/mL), goat biotinylated anti-human OPG (100 ng/mL) and
recombinant human OPG as standard reference in a range of
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For sRANKL detection, the following antibodies were used: goat anti-
human RANKL (2 μg/ml) and biotinylated goat anti-human RANKL
(0.2 μg/ml). The standard reference curve was set using recombinant
human sRANKL (Preprotech) with a range of 0.01-50 ng/ml.2.5. Alkaline phosphatase measurement
Alkaline phosphatase (ALP) was used as a marker of osteoblast
differentiation. ALP content was evaluated as previously described
[15]. Cytochemical alkaline phosphatase (ALP) analysis was per-
formed directly on conﬂuent cell culture plates using a commercial
kit (ALP leucocyte, Sigma, kit no 86-R). Cells were observed with a
light microscope and the presence of ALP was revealed by red
precipitates.
ALP activity was measured in cell lysates, with a biochemical
method based on the conversion of p-Nitrophenyl Phosphate Liquid
Substrate (Sigma-Aldrich). Semi-conﬂuent cells were lysed with 0.1%
Triton-X 160 100 (Sigma) in PBS for 10 min at 37 °C. After 15 min at
37 °C, the product of p-nitrophenyl phosphate reaction (Sigma) was
measured at 405 nm, and cell-associated ALP was expressed as M p-Fig. 1. Osteoblasts from MADA patient show normal differentiation. (A) Representative pic
osteoblast cultures. In (B) the histogram shows the mean±standard error of the ratios betw
(C) COL1A1/GAPDH, BGLAP/GAPDH and SPARC/GAPDHmRNA levels, as determined by Real T
microscopy analysis of differentiated control and MADA osteoblasts shows secretion ves
immunoﬂuorescence staining in differentiated control (CTRL HOB) and MADA osteoblasts (M
1 μm in (D) and 10 μm in (E).nitrophenol formed/cells. The experiments were performed in
duplicate.
2.6. Electron microscopy
Control and MADA HOB were ﬁxed with 2.5% glutaraldehyde –
0.1 M phosphate buffer pH 7.6 for 1 h at room temperature, postﬁxed
with 1% OsO4 in veronal buffer for 1 h, dehydrated in an ethanol
series, scraped, and embedded in epoxy resin. Ultrathin sections
counterstained with uranyl acetate-lead citrate were observed with a
Philips EM 400T electron microscope, operated at 100 KV. For each
sample, 100 nuclei were evaluated.
2.7. Western blot analysis
Whole cellular lysates from CTRL HOB or MADA HOB were lysed in
RIPA buffer [16] and subjected toWestern blot analysis. Proteins were
separated by a 5%–20% gradient SDS–PAGE. Protein bands were
blotted onto a nitrocellulose membrane and subjected to immunola-
beling using anti-TGF-beta rabbit polyclonal antibody (1:200 dilution,
Abcam), to detect intracellular TGFbeta levels or anti-actin antibody
(Santa Cruz), as a loading control. Anti-prelamin A (Sc-6214), anti-ture of the cytochemical ALP staining of control (CTRL HOB) and MADA (MADA HOB)
een millimoles of substrate converted by ALP in 1 min and the total amount of proteins.
ime PCR in control andMADA osteoblasts (means +/- standard error). (D) The electron
icles (v), hydroxyapatite crystals (HA) and collagen ﬁbrils (c). (E) Collagen Type I
ADA HOB). Data from three different experiments were evaluated. Bars, 50 μm in (A),
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and used at 1:100 dilution. Primary antibodies were applied for 1 h at
room temperature. Peroxidase-conjugated secondary antibodies
(Sigma) were applied for 20 min at room temperature. Immuno-
blotted bands were revealed by the Amersham ECL® detection
system. The intensity of bands was measured using a GS800
Densitometer (Biorad).2.8. Immunoﬂuorescence analysis
Cells were grown on glass coverslips and immunoﬂuorescence
staining was performed in proliferating CTRL HOB orMADAHOB ﬁxed
in 100% methanol. Anti-prelamin A Sc-6214 antibody was from Santa
Cruz, anti-lamin A/C monoclonal antibody was from Novocastra, anti-
collagen I antibody was from Sigma. Primary antibodies were applied
overnight at 1:100 dilution, secondary ﬂuorochrome-conjugated
antibodies were applied for 1 h. DNA was counterstained using
DAPI. Immunoﬂuorescence microscopy was performed using a Nikon
E600 epiﬂuorescence microscope and a Nikon oil-immersion objec-
tive [100× magniﬁcation, 1.3 NA (numerical aperture)]. Photographs
were taken using a Nikon digital camera (DXm) and NIS-Element
BR2.20 software (Nikon). All images were taken at similar exposures
within an experiment for each antibody. Image quantiﬁcation was
performed using NIS-Element BR2.20 software.Fig. 2.Osteoprotegerinexpressionand releasebyMADAosteoblasts is signiﬁcantly increased. (A
determined by real time PCR. (C) RANKL/osteoprotegerin ratio (mRNA levels). (D) (RANKL prot
threedifferent experiments. (E)Osteoprotegerinprotein levels, as determinedbyELISA.Values a
signiﬁcant difference. (F) RANKL/osteoprotegerin ratio (secreted protein levels), statistically sig
osteoblasts; MADA HOB, MADA osteoblasts.Images were processed using Adobe Photoshop 7.0 software
(Adobe Systems).
2.9. Statistical analysis
Statistical analysis was performed with the StatViewTM 5.0.1
software (SAS Institute, Inc., Cary, NC). Due to the low number of
experiments, data were considered distributed not normally and the
differences between groups were evaluated by a nonparametric test
(Mann–Whitney U-test). The level for signiﬁcance was taken as
Pb0.05.
3. Results
The clinical phenotype of the affected patient, bearing an R527H
homozygous LMNA mutation, was previously described [7,17]. The
presence of osteoporotic vertebrae is not a common feature of all
MADA patients, but it has been reported in a patient bearing a
homozygous A529T LMNA mutation [18]. Osteoblasts from controls
and MADA bone differentiated properly in osteoblast differentiation
medium. Fig. 1A and B show comparable alkaline phosphatase
staining in CTRL HOB and MADA HOB. Moreover, we did not detect
a signiﬁcant difference in the mRNA expression of the osteoblast
markers related to bone matrix deposition, like Type I collagen
(COL1A1), osteocalcin (BGLAP) and osteonectin (SPARC) that were)RANKLmRNA levels, asdeterminedbyreal timePCR. (B)OsteoprotegerinmRNAlevels, as
ein levels, as determined by ELISA. Values are reported asmeans+/- standard deviation of
re reported asmeans±standard error of threedifferent experiments. *pb0.05, statistically
niﬁcant difference, p=0.02. *, statistically signiﬁcant difference pb0.05; CTRL HOB, control
Fig. 3. TGFbeta 2 expression is signiﬁcantly increased inMADA osteoblasts. (A) TGFbeta 2mRNA levels in control andMADA osteoblasts. (B)Western blot analysis of TGFbeta protein
in osteoblast cellular lysates. Beta actin staining shows equal loading of samples. (C) Densitometric analysis of TGFbeta band obtained in three different experiments. CTRL HOB,
control osteoblast samples; MADA HOB, MADA osteoblast samples. Values are reported as means±standard error of three different experiments. *pb0.05, statistically signiﬁcant
difference.
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shown in Fig. 1C. Pictures reported in Fig. 1D show the ultrastructural
morphology of differentiated control and MADA osteoblasts. MADA
HOB showed altered nuclear morphology but proper chromatin
organization. Moreover, hydroxyapatite crystals and collagen ﬁbers
were deposited as in control cell cultures (Fig. 1D). Normal collagen
Type I deposition was supported by immunoﬂuorescence analysis of
the extracellular matrix protein (Fig. 1E, red staining). Collagen Type IFig. 4. Osteoclast differentiation and resorption activity is increased by MADA osteoblast con
the presence of conditioned medium from control (CTRL HOB) or MADA osteoblast (MADA
treated with MADA conditioned medium. Mean±standard error, *, Pb0.05. (B) Collagen Typ
medium. Mean±standard error, **, Pb0.01. (C) Collagen Type I degradation by osteoclasts ob
a CTRL HOB culture, added with an anti-TGF-beta 2 polyclonal antibody or not added. Mean
rabbit polyclonal) did not produce any effect (7641,25±878,088 vs 6965,0±215,055 Abs, ab
supernatants added with or not added with a control antibody, respectively).is a key constituent of bone extracellular matrix. Thus, we could not
detect any defect in MADA HOB differentiation activity.
Next, we examined by real-time PCR analysis the expression levels
of genes, whose products are known regulators of osteoclast
differentiation. Expression of the receptor activator of NF-kB ligand
(RANKL) in MADA HOB was increased with respect to control
cultures, although the difference was not statistically signiﬁcant
(Fig. 2A). On the contrary, a signiﬁcant increase of osteoprotegerinditioned medium. Control peripheral blood monocytes were induced to differentiate in
HOB) cultures. (A) Number of TRACP positive multinucleated cells in cultures of PBMC
e I degradation by osteoclasts obtained in the presence of MADA or control conditioned
tained in the presence of conditioned medium obtained from theMADA culture or from
±standard error, * or +, pb0.05. The treatment with a control antibody (anti-emerin,
sorbance from the Type I collagen degradation assay of PBMC incubated with HOB CTRL
Fig. 5. Prelamin A and lamin A/C analysis in MADA osteoblasts. Proliferating CTRL HOB (A, C, E) or MADA HOB (B, D, F) were double-labeled using anti-prelamin A (A, B) and anti-
lamin A/C (C, D) antibodies. TRITC-conjugated anti-goat IgG antibody (red) was used to reveal prelamin A, FITC-conjugated anti-mouse IgG was used to reveal lamin A/C. DAPI
staining of nuclei (E, F) is shown. Bar, 10 μm. (G) CTRL HOB and MADA HOB were subjected to Western blot analysis using anti-lamin A/C and anti-prelamin A Sc-6214 antibodies.
Actin levels were evaluated to show equal loading of samples. Molecular weight markers are reported in kDa.
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osteoprotegerin ratio of mRNA levels was diminished (Fig. 2C).
Moreover, while RANKL secreted protein levels were comparable in
controls and MADA HOB (Fig. 2D), protein levels of osteoprotegerin
were consistently increased in MADA HOB, as determined by ELISA
(Fig. 2E). Thus, the RANKL/osteoprotegerin ratio was diminished
(Fig. 2F). Protein levels of osteoprotegerinwere consistently increased
in MADA HOB, as determined by ELISA (Fig. 2E). Moreover, the mRNA
expression and the protein level of TGFbeta 2 were signiﬁcantly
increased (Fig. 3) in MADA HOB, further supporting an imbalance of
bone metabolism-related signaling. The reduced RANKL/osteoprote-
gerin ratio found in MADA cells suggested reduced stimulation of
osteoclast differentiation by the MADA osteoblast conditioned
medium, since a high RANKL/osteoprotegerin ratio is required for
osteoclast differentiation. Unexpectedly, the medium obtained from
MADA HOB cultures triggered differentiation of normal peripheral
blood-derived monocytes more efﬁciently than control osteoblast
medium (Fig. 4A). Moreover, we found that the collagen matrix
degradation activity of osteoclasts stimulated by MADA HOB
conditioned medium was signiﬁcantly increased with respect to
CTRL HOB media-stimulated osteoclasts (Fig. 4B). Notably, when a
neutralizing anti-TGF-beta-2 antibody was added to the conditioned
medium, the osteoclastogenic activity of MADA HOB supernatants
was signiﬁcantly impaired, whereas the activity of CTRL HOB super-
natants was unaffected (Fig. 4C). Addition of a control antibody to
conditioned media did not produce any effect.
In order to determine towhich extent lamin A/C defects affected the
nuclear phenotype of MADA osteoblasts, we labeled both prelamin A
and lamin A/C by immunoﬂuorescence staining. Fig. 5 shows the typical
increase of prelamin A levels observed in a percentage of MADA cells.
Here, 15% of MADA HOB showed prelamin A staining while the lamin A
precursor could not be detected in CTRL HOB (Fig. 5). The honeycomb
appearance of lamin A/C staining, which we recently linked to
anomalous prelamin A intermolecular interactions [19], was observed
in 60% of MADAHOB nuclei (Fig. 5B, arrowheads). Only 5% of CTRL HOB
nuclei showed honeycomb structures (not shown). Prelamin A was
detected by Western blot analysis in MADA HOB, but not in CTRL HOB,while comparable levels of lamin A/C were observed in CTRL HOB and
MADA HOB. Consistent with the low percentage of nuclei showing
prelamin A staining, low prelamin A levels were indicated by the
Western immunoblot.
4. Discussion
This study addresses the pathogenesis of bone defects found in
laminopathies, using primary osteoblasts bearing the homozygous
R527H LMNA mutation that causes MADA.
Our data show that MADA HOB derived from cervical vertebrae
undergo normal differentiation and are able to produce calciﬁed
matrix in vitro. However, cytokine production in MADA HOB seems to
be altered, as we report striking increase of osteoprotegerin and
moderate increase of TGFbeta 2 expression. Importantly, despite
the increase in osteoprotegerin levels, MADA HOB trigger osteoclast
differentiation and resorption activity to a higher rate with respect
to CTRL HOB, suggesting the activation of non-canonical differentia-
tion mechanisms possibly mediated by TGFbeta-dependent signaling
[20].
Previous reports showed that bone mineral density and osteoblast
number are reduced in mouse models of laminopathies, including the
Zmpste24−/− mice, which show a progeroid phenotype associated
with bone loss [10,21], and the progeria mouse model [22]. Based on
these data, it appears likely that prelamin A accumulation, which
occurs in the above mentioned experimental models and in MADA
cells [23], causes an imbalance in osteoclast and/or osteoblasts leading
to defective bone turnover and ultimately causing osteolysis. It is
noteworthy that osteoclasts accumulating prelamin A, either as a
result of protein mutation or under drug treatment, show normal or
enhanced differentiation rate [11]. In fact, it has been shown that
osteoclasts subjected to drugs inducing prelamin A accumulation
proliferate at normal rate and differentiate more efﬁciently than
the wild-type cells [11]. Here, we show normal differentiation rate
of cultured MADA osteoblasts. These data have been obtained
considering each cellular model independently of the other. However,
the altered bone turnover observed in laminopathies featuring
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between cells implicated in bone homeostasis [25]. In fact, we show
that cytokine production is altered in MADA osteoblasts, whose
secreted factors favor differentiation and matrix resorption activity of
osteoclasts.
On the other hand, the low level of prelamin A detected in MADA
osteoblasts suggests that not only accumulation of the toxic lamin A
precursor, but also the homozygous LMNA mutation itself may
interfere with fundamental interactions of lamin A, thus causing
altered expression of osteoblast-derived factors. The ﬁnding that
osteoprotegerin was strikingly increased in MADA osteoblast
cultures would have suggested reduced osteoclast activation by
osteoblast conditioned medium [2]. Contrary to what was expected,
osteoclasts differentiating in that medium showed a signiﬁcantly
increased bone resorption activity. These data indicate that a
molecular pathway not involving the canonical RANKL/osteoprote-
gerin balance [26] might be implicated in osteoclast activation in
MADA. Along this line, the ﬁnding that TGFbeta 2 levels are increased
in MADA osteoblasts, while inhibition of TGFbeta by a neutralizing
antibody reduces the osteoclastogenic potential of MADA-HOB
conditioned medium, might implicate this cytokine in osteoclast
activation. Consistent with this hypothesis, it has been demonstrated
that, in the absence of RANKL, TGFbeta is able to induce osteoclast
differentiation and activity in a RANKL-independent way, which is
not regulated by osteoprotegerin levels [20]. We hypothesize that
increased differentiation and resorption activity triggered by MADA
conditioned medium might reﬂect a TGFbeta 2-mediated activation,
which should overcome osteoprotegerin inhibition. Interestingly, a
similar increase in TGFbeta 2 and osteoprotegerin levels has been
found in serum from aged women and it has been shown to increase
with age [27].
One could speculate that the cytokine changes observed in MADA
osteoblasts could be associated with the premature aging phenotype
[28] or could independently cause clinical defects, such as osteopo-
rosis, typical of both progeroid laminopathies and aging [6,25,29].
Moreover, a clear link between another nuclear envelope protein,
MAN1, and TGFbeta expression and activity has been established and
implicated in bone disease [30], consistent with the increasing
evidence that proteins at the nuclear periphery regulate TGFbeta
and Smad dependent pathways [5,6,31].
It is noteworthy that TGFbeta has been implicated in the activation
of transcription factors that regulate nuclear positioning in osteoclasts
[32], a role also emerging for lamin-dependent pathways. The
following implications of the observed phenomena on MADA
pathogenesis and treatment can be envisaged. First, the relationship
between lamin A/mutated lamin A or prelamin A and TGFbeta 2
production deserves investigation, as well as the mechanism
underlying overexpression of osteoprotegerin. Intriguingly, osteopro-
tegerin increase has been reported in several disorders, also found in
MADA, such as altered adipose tissue metabolism and type 2 diabetes
[33,34]. Secondly, the possible presence of anomalous levels of
TGFbeta 2 in patients' serum should be evaluated. Finally, provided
that elevated levels of TGFbeta 2 are detected in serum, drugs capable
of reducing TGFbeta production/activity could prove useful to rescue
the bone phenotype in MADA patients.Acknowledgments
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